Cipla Secures FDA Approval for First U.S.-Manufactured Generic Advair Diskus Across All Three Strengths
核心洞察
Cipla Limited received U.S. FDA approval for its ANDA for generic Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in all three strengths: 100/50 mcg, 250/50 mcg, and 500/50 mcg.
The approval represents Cipla's first dry powder inhaler (DPI) approval from its U.S.-based manufacturing network, specifically its New York facility.
The U.S. market for fluticasone propionate and salmeterol inhalation powder is approximately $908 million, according to IQVIA data.
Cipla Limited, in conjunction with its wholly owned subsidiary Cipla USA Inc., announced on July 28, 2026 that it has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for generic Advair Diskus (fluticasone propionate and salmeterol inhalation powder). The approval covers all three dosage strengths — 100/50 mcg, 250/50 mcg, and 500/50 mcg — positioning Cipla to enter a U.S. market valued at approximately $908 million, according to IQVIA data.
The product is a therapeutically equivalent version of Advair Diskus, a widely prescribed combination therapy indicated for the treatment of asthma (搜索) and chronic obstructive pulmonary disease (搜索) (COPD). This milestone marks Cipla's first dry powder inhaler (DPI) approval from its U.S.-based manufacturing network, underscoring the company's expanding complex respiratory capabilities in the United States.
A Strategic Manufacturing Milestone
The approval represents a significant advancement in Cipla's U.S. manufacturing footprint. Marc Falkin, Chief Executive Officer of Cipla North America, emphasized the operational significance: "This approval marks our first dry powder inhaler from our New York facility and reflects our targeted investments in building differentiated inhalation manufacturing capabilities in the U.S. It strengthens our ability to provide reliable, high-quality supply in an important and competitive category."
The product is backed by Cipla's vertically integrated inhalation platform, reflecting the company's commitment to strengthening U.S. manufacturing capabilities for complex respiratory treatments. This integrated approach allows Cipla to control the entire production chain, from active pharmaceutical ingredient development through to finished dose manufacturing.
Leadership Perspective
Achin Gupta, Managing Director and Global CEO of Cipla Limited, highlighted the strategic importance of the approval within the company's broader respiratory portfolio: "At Cipla, we're passionate about respiratory care given our long-standing expertise. This approval reinforces our commitment to expanding access to complex therapies in the U.S. and highlights our strength in developing and scaling sophisticated inhalation products through integrated capabilities."
Market Context and Company Position
Cipla has established itself as a significant player in the global pharmaceutical landscape. The company is ranked third largest in pharmaceuticals in India, second largest in the pharmaceutical prescription market in South Africa, and second largest by prescription in the U.S. generic respiratory market for certain product categories, according to IQVIA data. With 46 manufacturing sites worldwide producing over 50 dosage forms and more than 1,500 products across 70-plus markets, Cipla brings substantial manufacturing scale to this new product launch.
The approval of generic Advair Diskus adds to Cipla's established strengths in respiratory, antiretroviral, urology, cardiology, anti-infective, and CNS therapeutic segments, further diversifying its U.S. generic portfolio in a therapeutically critical category.